Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis

Executive Summary

Amgen expects to receive approval by year-end for an Enbrel 50 mg pre-filled syringe that could simplify dosing of the TNF inhibitor for treatment of plaque psoriasis and other indications
Advertisement

Related Content

Amgen Enbrel (correction)
Amgen Enbrel (correction)
Genentech Misses Enbrel Deadline; Amgen Contract Facility Not Ready
Enbrel Once-Weekly Dosing Will Help “Neutralize” Humira Advantage – Amgen
Enbrel Once-Weekly Dosing Will Help “Neutralize” Humira Advantage – Amgen
Genentech/Xoma Raptiva Promotions Likely To Focus On Dosing Convenience
Amgen/Wyeth Enbrel Supplies Replenished With Rhode Island Plant Approval
Amgen Enbrel Rhode Island Facility To Get FDA Inspection In Early November
Immunex Enbrel Patient Starts After Jan. 1 Will Be Via Waiting List
Advertisement
UsernamePublicRestriction

Register

PS043954

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel